TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19102753
Drug: GINA guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: GINA guidelines treatment for 2 months
Study: 10588075
Drug: Baseline variables
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline variables (age and treatment assignment adjusted)
Study: 7496757
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen administered every 8 hours for 1-hour duration for a 2-week period
Study: 31831868
Drug: Saroglitazar 4
Normalized name: Saroglitazar 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar 4 mg daily for 4 months
Study: 28295959
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/d (first exposure)
Study: 28295959
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/d (second exposure)
Study: 28295959
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg/d (first and second exposure correlation)
Study: 26695794
Drug: Different drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drug therapies for type A (acute sensorineural hearing loss in low tone frequencies)
Study: 26695794
Drug: Different drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drug therapies for type C (acute sensorineural hearing loss in all frequencies)
Study: 26695794
Drug: Different drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drug therapies for type B (acute sensorineural hearing loss in high tone frequencies)
Study: 26695794
Drug: Different drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drug therapies for type D (total deafness)
Study: 26695794
Drug: Overall comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall comparison of four different treatment groups
Study: 17298707
Drug: SYN1 (spray‐dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN1 (spray‐dried mixture of chicory oligofructose and long‐chain inulin)
Study: 9514453
Drug: Atorvastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 80 mg/day
Study: 7698708
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 x 0.9% saline solution subcutaneously)
Study: 335793
Drug: s.c. heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. heparin alone
Study: 335793
Drug: s.c. heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. heparin + p.o. acenocoumarin
Study: 335793
Drug: s.c. heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. heparin (5000 IU twice daily)
Study: 25833163
Drug: Hib-MenAC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib-MenAC vaccine (administered in 2-dose series for 6-23 months and single dose for 2-5 years)
Study: 25833163
Drug: Licensed vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed vaccines (control group)
Study: 22056152
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) and radiation therapy (RT) (65‐69 Gy to the prostate and seminal vesicles, 45 Gy to the pelvic nodes)
Study: 7130340
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose estrogen (1/0.5 mg)
Study: 7130340
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose estrogen (2/1 mg)
Study: 7130340
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose estrogen (4/2 mg)
Study: 7130340
Drug: All hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hormone groups (low, medium, high)
Study: 7130340
Drug: Post-treatment values
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment values of S-aPh and U-HyPro
Study: 28214948
Drug: Fiix-warfarin patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiix-warfarin patients
Study: 28214948
Drug: PT-warfarin patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT-warfarin patients
Study: 24676313
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of Zn for 6 months
Study: 24676313
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of Zn for 6 months
Study: 22554019
Drug: 3.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5% lidocaine gel
Study: 17920374
Drug: Intravenous esmolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous esmolol (beta(1) blockade)
Study: 16135174
Drug: Adjustable dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable dose regimen
Study: 11755936
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg per oral)
Study: 2913252
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline used as a suspension in a gelatin sponge placed in the sockets of extracted mandibular third molars.
Study: 1093426
Drug: Intramuscular diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diazepam 10 mg
Study: 1093426
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and intramuscular diazepam
Study: 23560884
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (2 μg/kg)
Study: 23560884
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (2 μg/kg)
Study: 12512928
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg oral misoprostol every 3 hours
Study: 12512928
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg oral misoprostol every 6 hours
Study: 10335039
Drug: rhGH (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (recombinant human growth hormone) administered daily subcutaneously for 12 months, initial dose 0.125 IU/kg b.w./week, adjusted to maintain serum IGF-1 levels of 280-350 micrograms/L.
Study: 4569549
Drug: Oxytocin (Syntocinon)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (Syntocinon) administered in escalating doses
Study: 11392598
Drug: Oxytocin (by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (by intravenous infusion)
Study: 20399212
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (200 mg)
Study: 17654043
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of l-arginine and 75 mg of acetylsalicylic acid daily for 20 days
Study: 11796357
Drug: Caspofungin (35,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (35, 50, or 70 mg)
Study: 11796357
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 mg/kg)
Study: 11796357
Drug: Caspofungin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (any dose)
Study: 184912
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (RT) added to 15 months' maintenance actinomycin D (AMD) in Gp I patients under 2 years of age
Study: 30939487
Drug: COLM‐SST (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: COLM‐SST (25 mg of caraway oil and 20.75 mg of L‐menthol per capsule, at 2 capsules per dose, twice per day)
Study: 28577848
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cryothermal and bipolar radiofrequency (group 2)
Study: 20805005
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d) supplementation
Study: 16525137
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg once daily for 52 weeks
Study: 10809816
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) in combination with cyclosporin and prednisone (MMF+)
Study: 8852484
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (3 g/day with triglyceride preparation; 7.7 g/day with ethyl-ester preparation)
Study: 6391667
Drug: Antacid given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid given seven times a day combined with 600 mg BID of cimetidine (C + A7)
Study: 6391667
Drug: Antacid given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid given four times a day combined with cimetidine BID (C + A4)
Study: 6391667
Drug: Antacid alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid alone seven times daily (A7)
Study: 6391667
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (C + A7, C + A4, A7) compared to placebo
Study: 6391667
Drug: Cimetidine morning
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine morning dose
Study: 6391667
Drug: Cimetidine coadministration
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine coadministration with antacid
Study: 31633760
Drug: Pediatric-specific tumescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric-specific tumescent vasopressor solution and vasopressor-soaked topical compresses
Study: 22184058
Drug: Urinary cotinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary cotinine >1.3 ng ml(‐1)
Study: 17548089
Drug: Tibolone (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (1.25 or 2.5 mg/d)
Study: 10505303
Drug: Hepatitis C
Normalized name: hepatitis C virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis C virus (HCV) antibody
Study: 10505303
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B core antibody (HBcAb)
Study: 7039282
Drug: Lorcainide, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcainide, 100 mg twice daily
Study: 27043946
Drug: Continuous application
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous application of local anaesthetic through subcutaneous catheter
Study: 25780881
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic Acid (AA) 100 mg/kg infusion 6 hours before donor operation and subsequent infusion of 100 mg/kg every 6 hours until organ removal
Study: 23851059
Drug: Adaptive cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive cardiac resynchronization therapy (aCRT) with synchronized left ventricular pacing (sLVP)
Study: 18727647
Drug: Drug and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug and behavioural therapy for acute headache treatment
Study: 18727647
Drug: Invasive procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Invasive procedures (injections)
Study: 8039526
Drug: Oral drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drugs
Study: 16834790
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume (60 mL of anaesthetic solution)
Study: 16834790
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume (30 mL of anaesthetic solution)
Study: 9199943
Drug: Bamiphylline (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamiphylline (300 mg)
Study: 1287196
Drug: Two prototypical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two prototypical ethanol-water flux-enhanced transdermal therapeutic systems
Study: 4005127
Drug: Oros system
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oros system with initial release rate of 14 mg/h
Study: 4005127
Drug: Oros system
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oros system with initial release rate of 19 mg/h
Study: 3589362
Drug: Gestagen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestagen therapy (lynestrenol)
Study: 26962903
Drug: Trimethoprim-sulfamethoxazole (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (320 mg and 1600 mg, respectively, twice daily for 7 days)
Study: 20858114
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg triamcinolone acetonide monotherapy (n=17)
Study: 20858114
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg bevacizumab monotherapy (n=14)
Study: 20858114
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 mg triamcinolone acetonide and 1.25 mg bevacizumab (n=21)
Study: 15931282
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (60 mg/day elemental iron)
Study: 3036259
Drug: m-chlorophenylpiperazine (m-CPP)
Normalized name: m-phenylenediamine
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-chlorophenylpiperazine (m-CPP) 0.5 mg/kg
Study: 8096880
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide 0.2 mg
Study: 2879736
Drug: Loratadine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (160 mg)
Study: 2879736
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (4 mg)
Study: 22998983
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Stimulation Therapy (iCST) sessions delivered by a carer for 30 minutes, 3 times a week over 25 weeks
Study: 11810078
Drug: 20-cm² patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-cm² patch (Ortho Evra)
Study: 11810078
Drug: All patch
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patch regimens
Study: 1283730
Drug: IGF-I (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF-I (40 micrograms/kg by single subcutaneous dose)
Study: 30043192
Drug: Home-based sensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based sensory interventions plus standard therapy
Study: 30043192
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (speech therapy and applied behavior analysis)
Study: 22964975
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg/day) for 12 weeks
Study: 22097160
Drug: Multi-drug injection
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug injection (ropivacaine, morphine, ketorolac, and epinephrine)
Study: 22097160
Drug: Multi-drug injection
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug injection
Study: 10966889
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (providing 2.0 g EPA/d and 1.4 g DHA/d)
Study: 10966889
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (providing 12.3 g oleate/d)
Study: 10966889
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (providing 10.5 g linoleate/d)
Study: 9201636
Drug: Static stretch
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static stretch (30 seconds, twice daily)
Study: 9201636
Drug: Active stretch
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active stretch (30 repetitions of active knee extension while sitting in a neural slump position, twice daily)
Study: 30019970
Drug: 755-nm picosecond
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 755-nm picosecond pulsed alexandrite laser treatments (4 treatments, spaced 3 weeks apart)
Study: 30019970
Drug: 1927-nm fractionated
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1927-nm fractionated thulium laser treatments (2 treatments, spaced 6 weeks apart)
Study: 24283160
Drug: Red clover
Normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover isoflavones supplementation (60.8 mg red clover isoflavones plus 19.2 mg soy isoflavones)
Study: 21596867
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of autologous blood
Study: 21596867
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of autologous blood
Study: 21596867
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of autologous blood
Study: 18444850
Drug: Clarithromycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (1 g, intravenously once daily for 3 consecutive days)
Study: 14517188
Drug: Unpurged high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unpurged high-dose therapy (U)
Study: 14517188
Drug: Purged high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purged high-dose therapy (P)
Study: 9094873
Drug: Iron-fortified, cow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified, cow milk-based infant formula (465 mg Ca and 317 mg P/L)
Study: 9094873
Drug: Iron-fortified infant
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified infant formula with added calcium glycerophosphate (1800 mg Ca and 1390 mg P/L)
Study: 1098751
Drug: Althesin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Althesin (0.05 ml/kg)
Study: 30342394
Drug: FLZ tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLZ tablets, administered orally, dosage not specified, duration not specified
Study: 25960085
Drug: riluzole plus
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riluzole plus mexiletine 300 mg
Study: 25960085
Drug: riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riluzole 100 mg
Study: 19607949
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IVV) with 1 million units (Mu) of alpha interferon
Study: 19607949
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IVV) with 10 million units (Mu) of alpha interferon
Study: 19607949
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IVV) alone
Study: 17885853
Drug: Intranasal ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal ciclesonide 200 micro g once daily
Study: 17885853
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate-salmeterol (FP-SAL) 500 to 50 micro g twice daily
Study: 17885853
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg single dose
Study: 15236630
Drug: Roxil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxil (500 mg capsule)
Study: 15236630
Drug: Ultracef (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultracef (500 mg capsule)
Study: 12133499
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS), given once a day for 14 days, in subgroup with early TMS treatment.
Study: 12133499
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TMS), basic treatment same as TMS group.
Study: 9822239
Drug: 0.25% fluorometholone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% fluorometholone eyedrops four times daily before and after argon laser trabeculoplasty
Study: 9822239
Drug: Placebo eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eyedrops four times daily before and after argon laser trabeculoplasty
Study: 7484996
Drug: Combined bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bile acid therapy (chenodeoxycholic acid 500 mg/day and ursodeoxycholic acid 500 mg/day)
Study: 7484996
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid alone (1000 mg/day)
Study: 7484996
Drug: Combined bile
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bile acid therapy
Study: 7443776
Drug: Lithium salts
Normalized name: LITHIUM SALTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium salts with concomitant antidepressive medication (moderate doses for 4 weeks)
Study: 31782181
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) - 0.5g/kg on day 1, 1g/kg on day 2, 0.6g/kg on weeks 3 and 5
Study: 31782181
Drug: Volume-matched intravenous
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volume-matched intravenous normal saline (placebo)
Study: 26057085
Drug: 6% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydrogen peroxide bleaching agent